Benchmark Announces Appointment of Chuck Swoboda to Board of Directors
Mr. Swoboda brings over three decades of leadership in technology, innovation, and manufacturing experience to Benchmark's Board. He is the former Chairman and CEO of Cree, Inc., where he led the transformation of the company from a $177 million R&D-focused business into a $1.6 billion global leader in semiconductors and LED lighting. During his tenure, he championed a culture of innovation, launched thousands of new products, and helped secure over 5,000 patents, including 24 as a co-inventor.
'Chuck is a visionary leader whose track record in scaling advanced technology businesses and driving innovation aligns perfectly with Benchmark's strategic direction,' said Jeff Benck, President and CEO of Benchmark. 'Chuck's experience in semiconductors, IoT, and global operations will be invaluable as we continue to expand our complex solution capabilities and deliver further value to our customers.'
'Chuck's deep understanding of advanced manufacturing, operational excellence, and global supply chains will enhance our board's perspective,' said David W. Scheible, Chairman of the Board. 'We are excited to welcome him and look forward to his contributions.'
In addition to his role at Cree, Mr. Swoboda currently serves on the board of Ryder System, Inc. (NYSE: R) and has held board positions at Anixter International, Vesper Technologies, and several early-stage technology companies. He is also the author of The Innovator's Spirit and serves as Innovator-in-Residence at Marquette University. Mr. Swoboda holds a Bachelor of Science in Electrical Engineering from Marquette University.
To learn more about Benchmark's Board of Directors, please visit https://www.bench.com/board-of-directors.
About Benchmark Electronics, Inc.
Benchmark provides comprehensive solutions across the entire product lifecycle; leading through its innovative technology and engineering design services; leveraging its optimized global supply chain; and delivering world-class manufacturing services in the following industries: aerospace and defense, advanced computing and communications, industrial, medical, and semiconductor capital equipment. Benchmark's global operations include facilities in seven countries and its common shares trade on the New York Stock Exchange under the symbol BHE.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Strong Aerospace Performance Fuels Parker Hannifin To Record Profit
Parker Hannifin Corp. (NYSE:PH) stock is trading higher on Thursday after it reported fiscal fourth-quarter 2025 sales of record $5.24 billion, exceeding analyst expectations of $5.10 billion. Net income rose 18% year over year to $923 million, or $7.15 per diluted share, compared with $785 million, or $6.01 per share, a year ago. Adjusted earnings reached $992 million, or a record $7.69 per share, beating the consensus estimate of $7.11. In the Diversified Industrial segment, North America sales declined 6.9% to $2.08 billion, while segment operating margin expanded 200 basis points to 24.7%, or 170 basis points to 26.7% on an adjusted sales grew 4.3% to $1.49 billion, with margins improving 60 basis points to 22.4%, or 80 basis points to 24.7% adjusted. Order rates rose 2% in North America and remained flat internationally. Aerospace Systems revenue climbed 9.7% to $1.68 billion, driven by 8.6% organic growth. Segment operating income rose 23% to $407 million, while adjusted margin improved 190 basis points to a record 29.0%. The segment's backlog grew to a record $7.4 billion, with order rates up 12% year over year. For the full fiscal year, Parker reported revenue of $19.85 billion. Net income increased 24% to $3.53 billion, up from $2.84 billion in the prior year. Adjusted EPS was a record $27.33, rising 7% from $25.44. The full-year EBITDA margin reached 27.3%, or 26.4%, on an adjusted basis. View more earnings on PH Cash flow from operations increased 12% to $3.8 billion, or 19.0% of sales. Parker repurchased $1.6 billion in shares during the year, including $851 million in the fourth quarter. The company also raised its quarterly cash dividend by 10% and announced the acquisition of Curtis Instruments to expand its electrification capabilities. Parker ended the fiscal year with $467 million in cash and cash equivalents and $9.29 billion in total debt, including $1.79 billion due within one year. 'Looking ahead to fiscal year 2026, we expect Aerospace to remain our fastest growing business and see a return to positive organic growth in our Industrial businesses. We remain committed to being great generators and deployers of cash to drive shareholder value and look forward to another excellent year powered by our people and our business system,' commented Chairman and CEO Jenny Parmentier. Outlook For fiscal 2026, the company expects sales growth of 2%-5%, including approximately 3% organic growth at the midpoint. Segment operating margin is projected to range from 23.3% to 23.7%, or 26.3% to 26.7% on an adjusted basis. EPS guidance is between $24.68 and $25.68 versus the consensus of $25.778, and $28.40 to $29.40 on an adjusted basis versus the consensus of $28.873. Price Action: At last check Thursday, PH shares were trading higher by 3.18% to $719.29. Read Next:Photo by JHVEPhoto via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? PARKER HANNIFIN (PH): Free Stock Analysis Report This article Strong Aerospace Performance Fuels Parker Hannifin To Record Profit originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
AIS Healthcare Awarded a Group Purchasing Agreement for 503A Intrathecal Compounded Medications with Premier, Inc.
DALLAS--(BUSINESS WIRE)--AIS Healthcare has been awarded a group purchasing agreement for 503A intrathecal compounded medications with Premier, Inc., effective July 1, 2025. The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for sterile, patient-specific intrathecal pain pump medications. In addition, to assist with compliance policies, this agreement with Premier will provide member hospitals with site audit evaluations as well as ongoing quality reporting. 'Partnering with Premier allows us to bring our high‑quality, patient‑specific medications and services to more patients and providers across the country. By combining Premier's expansive network with our expertise in delivering safe, reliable, and longer‑dated compounded medications, we can help meet the growing 503A outsourcing needs for Premier's member organizations with confidence and consistency. Together, we are delivering the best possible care to patients,' said Simon Castellanos, CEO of AIS Healthcare. Premier, Inc. is a leading healthcare improvement company, bringing more than 4,400 US hospitals and health systems and approximately 250,000 other providers and organizations together to transform health care. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost. About AIS Healthcare AIS Healthcare is a 503A pharmacy that compounds intrathecal medications for Targeted Drug Delivery (TDD). As the leading provider of TDD, AIS Healthcare is committed to providing industry leading intrathecal medications and the highest quality care. At the center of our TDD operation are our 2 state-of-the-art 503A specialty compounding pharmacies, which prepare and ship more than 145,000 patient-specific prescriptions annually. At both facilities, we go beyond industry and state standards to produce medications of the highest quality. We use a proven, proprietary process that combines aseptic processing with terminal sterilization on patient-specific prescriptions to achieve higher sterility assurance and extended Beyond-Use Dates (BUD). To learn more about AIS Healthcare, please contact Chad Jeske at cjeske@ or visit our website at
Business Wire
an hour ago
- Business Wire
Cushman & Wakefield Announces Renewed Science-Based Greenhouse Gas Emissions Reduction Targets
NEW YORK--(BUSINESS WIRE)--Cushman & Wakefield (NYSE: CWK), a leading global commercial real estate services firm, today announced renewed science-based greenhouse gas (GHG) emissions reduction targets that raise the bar on climate ambition across its operations and the client properties it manages worldwide. Cushman & Wakefield today announced renewed science-based greenhouse gas emissions reduction targets that raise the bar on climate ambition across its operations and the client properties it manages worldwide. Share The updated targets introduce higher emissions reduction objectives and a refined methodology for addressing the Scope 3 emissions that make up the vast majority of its value chain footprint. Cushman & Wakefield Operations: Reduce absolute Scope 1 and 2 GHG emissions across Cushman & Wakefield corporate offices and operations by 73.1% by 2034. This target reflects an increase in ambition following strong progress toward the firm's original 50% reduction goal that was set for 2030. Managed Client Properties: Reduce Scope 3 GHG emissions by 66.3% per square foot of managed area for clients by 2034. This new intensity‑based target replaces the firm's previous Scope 3 client engagement commitment with a more robust emissions‑intensity metric aligned to the performance of properties the firm manages on its clients' behalf which are within Cushman & Wakefield's operational control boundary. Net-Zero Value Chain: Maintain commitment to reach net‑zero emissions across the entire value chain (Scopes 1, 2 and 3) by 2050 in line with the Science Based Targets initiative (SBTi) Corporate Net‑Zero Standard. 'Since first setting science‑based targets in 2021, we've worked hard to reduce our own operational footprint and help clients decarbonize the buildings they own and occupy,' said Jessica Francisco, Cushman & Wakefield's Chief Sustainability Officer. 'With these renewed targets, we are reaffirming our progress to date and our intent to go further, faster.' Cushman & Wakefield established its first near‑term, SBTi‑approved targets in September 2021 and, in July 2022, became one of the first companies to have a net‑zero target approved under the SBTi's Corporate Net‑Zero Standard. In the years since, the firm has continued to invest in data management improvements, renewable electricity procurement and partnering with clients to deliver shared, sustainable value. These efforts, among others, have informed the firm's decision to commit to the next generation of targets. The firm intends to report annually on progress toward its 2034 targets through its annual Sustainability Report, in addition to other voluntary and regulatory disclosures, as applicable. Cushman & Wakefield believes these targets are important in the global effort to mitigate the adverse impacts of climate change and will assess them as necessary, based on SBTi guidelines and the evolution of the firm's strategy. 'Our clients are asking for data‑driven pathways to net zero. By expanding our Scope 3 target from an engagement metric to an emissions intensity target, we're aligning our services and accountability with what matters most—real decarbonization in the built environment,' said Francisco. Learn more about sustainability at Cushman & Wakefield and read the firm's recently published 2024 Sustainability Report here. About Cushman & Wakefield Cushman & Wakefield (NYSE: CWK) is a leading global commercial real estate services firm for property owners and occupiers with approximately 52,000 employees in nearly 400 offices and 60 countries. In 2024, the firm reported revenue of $9.4 billion across its core service lines of Services, Leasing, Capital markets, and Valuation and other. Built around the belief that Better never settles, the firm receives numerous industry and business accolades for its award-winning culture. For additional information, visit
